(Vall d'Hebron Institute of Oncology) Latest discovery promises new weaponry against dormant tumor cells to counteract resistance and prevent disease relapse. Findings show epigenetic enzyme TET2 as an orchestrator of the control and survival of these cells as promoters of cancer recurrence. TET2 inhibition proposed as an effective approach to prevent their seeding of metastasis. Novel biomarker identified for DTC detection and to more precisely predict those patients at risk of recurrence.
